|
1
|
Lechat P, Packer M, Chalon S, Cucherat M,
Arab T and Boissel JP: Clinical effects of beta-adrenergic blockade
in chronic heart failure: a meta-analysis of double-blind,
placebo-controlled, randomized trials. Circulation. 98:1184–1191.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Packer M: The neurohormonal hypothesis: A
theory to explain the mechanism of disease progression in heart
failure. J Am Coll Cardiol. 20:248–254. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doughty RN, Rodgers A, Sharpe N and
MacMahon S: Effects of beta-blocker therapy on mortality in
patients with heart failure: A systematic overview of randomized
controlled trials. Eur Heart J. 18:560–565. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heidenreich PA, Lee TT and Massie BM:
Effect of beta-blockade on mortality in patients with heart
failure: a meta-analysis of randomized clinical trials. J Am Coll
Cardiol. 30:27–34. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Gobari M, El Khatib C, Pillon F and
Gueyffier F: β-Blockers for the prevention of sudden cardiac death
in heart failure patients: a meta-analysis of randomized controlled
trials. BMC Cardiovasc Disord. 13:522013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higgins JPT, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Anderson JL, Lutz JR, Gilbert EM, Sorensen
SG, Yanowitz FG, Menlove RL and Bartholomew M: A randomized trial
of low-dose beta-blockade therapy for idiopathic dilated
cardiomyopathy. Am J Cardiol. 55:471–475. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jadad AR, Moore RA, Carroll D, Jenkinson
C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of
reports of randomized clinical trials: Is blinding necessary?
Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piccini JP, Berger JS and O'Connor CM:
Amiodarone for the prevention of sudden cardiac death: A
meta-analysis of randomized controlled trials. Eur Heart J.
30:1245–1253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beta-Blocker Evaluation of Survival Trial
Investigators: A trial of the beta-blocker bucindolol in patients
with advanced chronic heart failure. N Engl J Med. 344:1659–1667.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
No authors listed: Randomised,
placebo-controlled trial of carvedilol in patients with congestive
heart failure due to ischaemic heart disease. Australia/New Zealand
Heart Failure Research Collaborative Group. Lancet. 349:375–380.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chadda K, Goldstein S, Byington R and Curb
JD: Effect of propranolol after acute myocardial infarction in
patients with congestive heart failure. Circulation. 73:503–510.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bristow MR, O'Connell JB, Gilbert EM,
French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML,
Marshall G and Kelly P: Bucindolol Investigators: Dose-response of
chronic beta-blocker treatment in heart failure from either
idiopathic dilated or ischemic cardiomyopathy. Bucindolol
Investigators. Circulation. 89:1632–1642. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bristow MR, Gilbert EM, Abraham WT, Adams
KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H,
Krueger S, et al: Carvedilol produces dose-related improvements in
left ventricular function and survival in subjects with chronic
heart failure. MOCHA Investigators. Circulation. 94:2807–2816.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dargie HJ: Effect of carvedilol on outcome
after myocardial infarction in patients with left-ventricular
dysfunction: the CAPRICORN randomised trial. Lancet. 357:1385–1390.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
No authors listed: The Cardiac
Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial.
Lancet. 353:9–13. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
No authors listed: A randomized trial of
beta-blockade in heart failure. The Cardiac Insufficiency
Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.
Circulation. 90:1765–1773. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Witchitz S, Cohen-Solal A, Dartois N,
Weisslinger N, Juste K and Darmon JY: Treatment of heart failure
with celiprolol, a cardioselective beta blocker with beta-2 agonist
vasodilatory properties. The CELICARD Group. Am J Cardiol.
85:1467–1471. 2000. View Article : Google Scholar
|
|
20
|
Colucci WS, Packer M, Bristow MR, Gilbert
EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF,
Bowers JA, et al: Carvedilol inhibits clinical progression in
patients with mild symptoms of heart failure. US Carvedilol Heart
Failure Study Group. Circulation. 94:2800–2806. 1996.
|
|
21
|
Packer M, Fowler MB, Roecker EB, Coats
AJS, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C,
et al: Carvedilol Prospective Randomized Cumulative Survival
(COPERNICUS) Study Group: Effect of carvedilol on the morbidity of
patients with severe chronic heart failure: Results of the
carvedilol prospective randomized cumulative survival (COPERNICUS)
study. Circulation. 106:2194–2199. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Milliano PA, de Groot AC, Tijssen JG,
van Eck-Smit BL, Van Zwieten PA and Lie KI: Beneficial effects of
metoprolol on myocardial sympathetic function: Evidence from a
randomized, placebo-controlled study in patients with congestive
heart failure. Am Heart J. 144:E32002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Conraads VM, Metra M, Kamp O, De Keulenaer
GW, Pieske B, Zamorano J, Vardas PE, Böhm M and Dei Cas L: Effects
of the long-term administration of nebivolol on the clinical
symptoms, exercise capacity, and left ventricular function of
patients with diastolic dysfunction: results of the ELANDD study.
Eur J Heart Fail. 14:219–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Engelmeier RS, O'Connell JB, Walsh R, Rad
N, Scanlon PJ and Gunnar RM: Improvement in symptoms and exercise
tolerance by metoprolol in patients with dilated cardiomyopathy: A
double-blind, randomized, placebo-controlled trial. Circulation.
72:536–546. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fisher ML, Gottlieb SS, Plotnick GD,
Greenberg NL, Patten RD, Bennett SK and Hamilton BP: Beneficial
effects of metoprolol in heart failure associated with coronary
artery disease: A randomized trial. J Am Coll Cardiol. 23:943–950.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hansteen V, Møinichen E, Lorentsen E,
Andersen A, Strøm O, Søiland K, Dyrbekk D, Refsum AM, Tromsdal A,
Knudsen K, et al: One year's treatment with propranolol after
myocardial infarction: Preliminary report of Norwegian multicentre
trial. Br Med J (Clin Res Ed). 284:155–160. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krum H, Sackner-Bernstein JD, Goldsmith
RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz
SD, et al: Double-blind, placebo-controlled study of the long-term
efficacy of carvedilol in patients with severe chronic heart
failure. Circulation. 92:1499–1506. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Waagstein F, Bristow MR, Swedberg K,
Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG
and Hjalmarson A: Beneficial effects of metoprolol in idiopathic
dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC)
Trial Study Group. Lancet. 342:1441–1446. 1993.
|
|
29
|
No authors listed: Effect of metoprolol
CR/XL in chronic heart failure: Metoprolol CR/XL Randomised
Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet.
353:2001–2007. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Metra M, Nardi M, Giubbini R and Dei Cas
L: Effects of short- and long-term carvedilol administration on
rest and exercise hemodynamic variables, exercise capacity and
clinical conditions in patients with idiopathic dilated
cardiomyopathy. J Am Coll Cardiol. 24:1678–1687. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Olsen SL, Gilbert EM, Renlund DG, Taylor
DO, Yanowitz FD and Bristow MR: Carvedilol improves left
ventricular function and symptoms in chronic heart failure: A
double-blind randomized study. J Am Coll Cardiol. 25:1225–1231.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Packer M, Bristow MR, Cohn JN, Colucci WS,
Fowler MB, Gilbert EM and Shusterman NH: The effect of carvedilol
on morbidity and mortality in patients with chronic heart failure.
U.S. Carve-dilol Heart Failure Study Group. N Engl J Med.
334:1349–1355. 1996.
|
|
33
|
Pollock SG, Lystash J, Tedesco C, Craddock
G and Smucker ML: Usefulness of bucindolol in congestive heart
failure. Am J Cardiol. 66:603–607. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
No authors listed: Effects of metoprolol
CR in patients with ischemic and dilated cardiomyopathy: the
randomized evaluation of strategies of left ventricular dysfunction
pilot study. Circulation. 101:378–384. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Flather MD, Shibata MC, Coats AJS, van
Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu
D, Ferrari R, Lechat P, et al: Randomized trial to determine the
effect of nebivolol on mortality and cardiovascular hospital
admission in elderly patients with heart failure (SENIORS). Eur
Heart J. 26:215–225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sturm B, Pacher R, Strametz-Juranek J,
Berger R, Frey B and Stanek B: Effect of beta 1 blockade with
atenolol on progression of heart failure in patients pretreated
with high-dose enalapril. Eur J Heart Fail. 2:407–412. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Uhlir O, Dvorak I, Gregor P, Malek I,
Spinarova L, Vojacek J and Van Nueten L: Nebivolol in the treatment
of cardiac failure: A double-blind controlled clinical trial. J
Card Fail. 3:271–276. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wisenbaugh T, Katz I, Davis J, Essop R,
Skoularigis J, Middlemost S, Röthlisberger C, Skudicky D and Sareli
P: Long-term (3-month) effects of a new beta-blocker (nebivolol) on
cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol.
21:1094–1100. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Woodley SL, Gilbert EM, Anderson JL,
O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K,
Renlund DG and Menlove R: Beta-blockade with bucindolol in heart
failure caused by ischemic versus idiopathic dilated
cardiomyopathy. Circulation. 84:2426–2441. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bonet S, Agusti A, Arnau JM, Vidal X,
Diogène E, Galve E and Laporte JR: Beta-adrenergic blocking agents
in heart failure: benefits of vasodilating and non-vasodilating
agents according to patients' characteristics: a meta-analysis of
clinical trials. Arch Intern Med. 160:621–627. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hanania NA, Singh S, El-Wali R, Flashner
M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S,
Shardonofsky F, et al: The safety and effects of the beta-blocker,
nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol
Ther. 21:134–141. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Larochelle P, Tobe SW and Lacourcière Y:
β-Blockers in Hypertension: studies and meta-analyses over the
years. Can J Cardiol. 30 Suppl 5:S16–S22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matowa PR: Beta Blockers Use in Cardiac
Failure: Does the Current Prescribing Practice at a Large Urban
Hospital in Zimbabwe Exhibit Evidence Based Care and Offer Optimal
Therapy for Cardiac Failure Patients? Pharmacology & Pharmacy.
6:267–279. 2015. View Article : Google Scholar
|
|
44
|
Bangalore S, Makani H, Radford M, Thakur
K, Toklu B, Katz SD, DiNicolantonio JJ, Devereaux PJ, Alexander KP,
Wetterslev J and Messerli FH: Clinical outcomes with β-blockers for
myocardial infarction: a meta-analysis of randomized trials. Am J
Med. 127:939–953. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bavishi C, Chatterjee S, Ather S, Patel D
and Messerli FH: Beta-blockers in heart failure with preserved
ejection fraction: A meta-analysis. Heart Fail Rev. 20:193–201.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lu H, Liu X, Guo F, Tan S, Wang G, Liu H,
Wang J, He X, Mo Y and Shi B: Impact of beta-blockers on prostate
cancer mortality: a meta-analysis of 16,825 patients. Onco Targets
Ther. 8:985–990. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Andrews TC, Reimold SC, Berlin JA and
Antman EM: Prevention of supraventricular arrhythmias after
coronary artery bypass surgery. A meta-analysis of randomized
control trials. Circulation. 84 Suppl 5:III236–III244. 1991.
|
|
48
|
Chatterjee S, Biondi-Zoccai G, Abbate A,
D'Ascenzo F, Castagno D, van Tassell B, Mukherjee D and Lichstein
E: Benefits of β blockers in patients with heart failure and
reduced ejection fraction: network meta-analysis. BMJ. 346:f552013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ma ST, Zhao W, Liu B, Jia RY, Zhao CJ and
Cui LQ: Association between β1 adrenergic receptor gene Arg389Gly
polymorphism and risk of heart failure: a meta-analysis. Genet Mol
Res. 14:5922–5929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mostafaie K, Bedenis R and Harrington D:
Beta-adrenergic blockers for perioperative cardiac risk reduction
in people undergoing vascular surgery. Cochrane Database Syst Rev.
1:CD0063422015.PubMed/NCBI
|
